Eloxx Pharmaceuticals Inc (OTCPK:ELOX)
$ 0.72 -0.02 (-2.7%) Market Cap: 2.26 Mil Enterprise Value: 3.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Eloxx Pharmaceuticals Inc Topline ELX-02 Phase 2 Combination Results Call Transcript

Sep 14, 2022 / 08:30PM GMT
Release Date Price: $15.2 (+0.24%)
Operator

Good afternoon. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Eloxx Pharmaceuticals Conference Call. (Operator Instructions) Mr. John Woolford, Head of Investor Relations, you may begin your conference.

John Woolford

Thank you, operator. Good afternoon, and thank you to everyone who has joined today's call and webcast to discuss topline ELX-02 cystic fibrosis Phase II combination clinical trial results. A press release detailing the results was issued this afternoon and is currently available at www.eloxxpharma.com. An audio archive of the webcast will be available on Eloxx Pharmaceuticals website in the Investor Relations section later today. Also, please note that there are slides to accompany today's event. These slides are also available on the IR website.

Before we begin with prepared remarks, turning to Slide 2, I need to remind you that we will be making forward-looking statements during this teleconference that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot